Antengene raises $120m amid China anti-cancer push

It is the fourth nine-figure private fundraising by a Chinese pharmaceutical company involved in cancer research in nine months.

Antengene has become the fourth Chinese biopharmaceutical company in less than a year to raise well over $100 million from private investors, illustrating the country's growing efforts to develop effective anti-cancer drugs.

Shanghai-based Antengene said it completed a $120 million Series B fundraising on Wednesday to finance more research and invest in marketing for its ATG-008 anti-cancer drug, which is already undergoing Phase II clinical trials and so is being tried out on patients. 

Last year, three other China pharmaceutical companies attracted nine-figure sums including CStone Pharmaceutical $260 million, I-MAB Biopharma $220 million, and...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222